论文部分内容阅读
目的探讨乙肝新疗法与ＢＣＧ、潘生丁联合抗ＨＢＶ的作用。方法选择ＨＢｅＡｇ阳性乙肝病人５１２例，１∶２０００ＯＴ试验局部红肿、硬结＜７ｍｍ者，于三角肌外侧皮内注射卡介苗（ＢＣＧ）０．１ｍｌ，每月１次。同时口服潘生丁５０ｍｇ，２次／ｄ，连用４～８个月，治疗前后进行肝功、乙肝５项标志物检测。结果症状体征改善多优于９０例的对照组。ＨＢｓＡｇ阴转率和ＨＢｓＡｂ阳转率：治疗组分别为５．４７％与８．２０％；对照组为５．５６％与９．８６％，差异无显著性。ＨＢｅＡｇ阴转率与ＨＢｅＡｂ阳转率：治疗组分别为６０．３５％与３１．６２％；对照组分别为１３．３３％与１２．９９％，差异非常显著（Ｐ＞０．０１）。结论研究结果提示两药联用有协同抗ＨＢＶ作用，从而达到可靠地控制ＨＢＶ和改善肝功能效果，而无严重不良反应发生。
Objective To explore the new anti-hepatitis B therapy and BCG, dipyridamol combined anti-HBV role. Methods 512 patients with HBeAg-positive hepatitis B were selected. Local redness and induration of 1: 2000OT test were less than 7mm, and 0.1ml BCG (0.1ml BCG) was injected intradermally into the deltoid muscle once a month. At the same time oral dipyridamole 50mg, 2 times / d, once every 4 to 8 months, before and after treatment of liver function, hepatitis B five markers. Results Symptoms and signs improved more than 90 cases of control group. HBsAg negative rate and HBsAb positive rate: the treatment group were 5.47% and 8.20%; control group was 5.56% and 9.86%, the difference was not significant. The HBeAg negative rate and HBeAb positive rate were 60.35% and 31.62% respectively in the treatment group and 13.33% and 12.99% in the control group, respectively. The difference was significant (P> 0.01). Conclusions The results suggest that synergistic anti-HBV effect in combination with the two drugs can lead to the reliable control of HBV and the improvement of liver function without serious adverse reactions.